Question 1

What is the difference between GIP and GLP-1?

Accepted Answer

GIP and GLP-1 are both incretin hormones that potentiate insulin secretion after meals, but they differ in source, receptor distribution, and metabolic effects. GIP is secreted by K-cells in the upper small intestine and contributes ~60-70% of the incretin effect in healthy individuals, while GLP-1 is secreted by L-cells in the lower intestine and ileum. GLP-1 also suppresses glucagon secretion and slows gastric emptying — effects that GIP does not share to the same degree. In type 2 diabetes, GIP's insulinotropic effect is blunted while GLP-1's is preserved, which initially made GLP-1 the more attractive drug target.

Question 2

Why is GIP relevant to tirzepatide?

Accepted Answer

Tirzepatide is a dual GIP/GLP-1 receptor agonist — its peptide sequence is based on the GIP backbone with modifications that also activate the GLP-1 receptor. The addition of GIP agonism appears to enhance tirzepatide's metabolic effects beyond what GLP-1 alone achieves, potentially through improved lipid handling in adipose tissue, enhanced fat oxidation, and better gastrointestinal tolerability at high doses. In head-to-head trials, tirzepatide achieved greater weight loss and glycemic control than the selective GLP-1 agonist semaglutide.

Question 3

Can GIP be taken as a supplement or injection?

Accepted Answer

Native GIP cannot be used therapeutically because DPP-4 enzymes in the bloodstream degrade it within minutes, giving it a half-life of only 5-7 minutes. DPP-4 inhibitors (like sitagliptin) work partly by preventing GIP degradation, extending its activity. Direct GIP receptor agonists for standalone therapeutic use are in early research. The practical way to harness GIP pharmacology today is through dual agonists like tirzepatide, which use fatty acid acylation and sequence modifications to resist DPP-4 degradation.

Question 4

Does GIP cause weight gain or weight loss?

Accepted Answer

This is one of the most debated questions in incretin biology. GIP promotes lipid uptake into adipocytes, which initially suggested it might promote fat storage and weight gain. However, tirzepatide — which agonizes the GIP receptor — produces greater weight loss than GLP-1 agonists alone. The resolution may be that GIP's effects are context-dependent: in the setting of caloric excess, GIP facilitates efficient fat storage, but when combined with GLP-1's appetite-suppressing effects, GIP agonism may enhance fat oxidation and improve metabolic flexibility. Central GIPR activation also appears to contribute to satiety.

Question 5

What happens to GIP signaling in type 2 diabetes?

Accepted Answer

In type 2 diabetes, the insulinotropic response to GIP is markedly reduced — a phenomenon called GIP resistance. Beta cells in diabetic patients show decreased GIPR expression and impaired downstream cAMP signaling. This is why early incretin-based therapies focused on GLP-1 rather than GIP. However, supraphysiological doses of GIP agonists (as achieved with tirzepatide) can partially overcome this resistance. Additionally, restoring glycemic control with initial therapy appears to resensitize beta cells to GIP, suggesting that GIP resistance is at least partially reversible.

Question 6

Does GIP affect bone health?

Accepted Answer

GIP has a well-documented role in bone metabolism. GIPR is expressed on osteoblasts and osteoclasts, and postprandial GIP secretion suppresses bone resorption markers (CTX) while promoting bone formation. This is thought to contribute to the coupling of nutrient intake with bone preservation. In animal models, GIPR knockout mice show reduced bone mineral density. Clinically, this is relevant because GLP-1 agonists alone do not appear to have significant bone effects, while the addition of GIP agonism in tirzepatide may confer bone-protective benefits — though this has not yet been confirmed in dedicated bone outcome trials.

Question 7

What foods or dietary factors stimulate GIP secretion?

Accepted Answer

GIP is primarily stimulated by dietary fat and carbohydrates. Meals rich in long-chain fatty acids and simple sugars trigger the most robust GIP release from K-cells in the duodenum and jejunum, with secretion beginning within minutes of nutrient contact with the intestinal mucosa. Protein also stimulates GIP secretion but to a lesser degree than fat or glucose. Notably, GIP levels remain elevated for several hours after a high-fat meal, which has implications for postprandial lipid handling and the metabolic response to different macronutrient compositions.

Question 8

Does GIP have any effects on the cardiovascular system?

Accepted Answer

GIP receptors are expressed in cardiac tissue and vascular endothelium, and emerging research suggests GIP may have direct cardiovascular effects. Preclinical studies indicate that GIP can promote vasodilation, reduce inflammation in atherosclerotic plaques, and exert cardioprotective effects during ischemia-reperfusion injury. In the SURPASS-4 trial, tirzepatide (a dual GIP/GLP-1 agonist) showed a favorable cardiovascular safety profile in patients with type 2 diabetes at high cardiovascular risk, though a dedicated cardiovascular outcomes trial (SURPASS-CVOT) is needed to confirm whether GIP agonism contributes independently to cardiac benefit.

Question 9

What is the role of GIP in retatrutide, the triple agonist?

Accepted Answer

Retatrutide is a triple receptor agonist targeting GIP, GLP-1, and glucagon receptors simultaneously. GIP agonism in retatrutide is thought to complement GLP-1's appetite-suppressing effects while glucagon receptor activation adds enhanced energy expenditure and hepatic fat reduction. In phase 2 trials, retatrutide achieved up to 24% body weight loss at 48 weeks, exceeding results seen with dual GIP/GLP-1 agonists alone. The precise individual contribution of each receptor component remains under investigation, but the inclusion of GIP agonism appears important for optimizing metabolic outcomes and gastrointestinal tolerability.

Question 10

How do DPP-4 inhibitors like sitagliptin affect GIP levels?

Accepted Answer

DPP-4 inhibitors (gliptins) work by blocking dipeptidyl peptidase-4, the enzyme responsible for rapidly degrading both GIP and GLP-1. By inhibiting DPP-4, these drugs approximately double circulating levels of intact, active GIP and GLP-1 after meals, extending their biological half-lives from minutes to hours. However, because DPP-4 inhibitors only raise incretin levels to the physiological range rather than supraphysiological concentrations, their effects on weight and glycemic control are more modest than those of injectable GIP or GLP-1 receptor agonists like tirzepatide or semaglutide.

Origin / Manufacturer	Endogenous / Synthetic analogs
Active Components	GIP peptide (42 amino acids)
Storage	Lyophilized: -20°C. Reconstituted: 2-8°C
Shelf Life	Research-grade lyophilized: 12+ months at -20°C
Form Factor	Endogenous hormone; synthetic analogs available as research reagents

GIP (Glucose-Dependent Insulinotropic Polypeptide)

Specifications

Clinical Evidence

Frequently Asked Questions

Related Peptides

Liraglutide

Retatrutide

Semaglutide

Tirzepatide